Literature DB >> 3516755

Diclofenac sodium versus acetylsalicylic acid: a randomized study in febrile patients.

R Bettini, E Grossi, P Rapazzini, G Giardina.   

Abstract

One hundred and twenty adult patients with high temperatures (greater than or equal to 38 degrees C) brought about by influenza viruses or other conditions were randomly treated with two different antipyretics: a) a 25 mg sodium diclofenac tablet (Novapirina) every 12 hours for 2 consecutive days; b) a 500 mg tablet of acetylsalicylic acid (Aspirin) every 8 hours for 2 consecutive days. Antipyretic action (assessed at 6 hours following the first administration) was found to be equally rapid and consistent in both cases but significantly longer-lasting in the Novapirina-treated group than the Aspirin-treated group (p less than 0.01). Mean temperature changes over the 48 hours of observation and the over-all judgement on the antipyretic effect expressed at the end of each day of treatment were similar for both groups and good in all cases. The antiphlogistic-painkilling properties of both drugs were found to be effective in improving the symptomatology accompanying the high temperature during the course of the bout of influenza. The effectiveness/tolerability ratio was found to be satisfactory for both groups: only one case of gastric intolerance to Novapirina was recorded and five cases of gastric intolerance to Aspirin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516755     DOI: 10.1177/030006058601400208

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  8 in total

1.  Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.

Authors:  Ronald Esser; Carol Berry; Zhengming Du; Janet Dawson; Alyson Fox; Roger A Fujimoto; William Haston; Earl F Kimble; Julie Koehler; Jane Peppard; Elizabeth Quadros; Joseph Quintavalla; Karen Toscano; Laszlo Urban; John van Duzer; Xiaoli Zhang; Siyuan Zhou; Paul J Marshall
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 2.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

3.  Lowest effective single dose of diclofenac for antipyretic and analgesic effects in acute febrile sore throat.

Authors:  P Gehanno; R L Dreiser; E Ionescu; Morris Gold; Jiun-Min Liu
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

4.  Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care.

Authors:  Manuela Cormio; Giuseppe Citerio
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

5.  Randomized controlled study of the antipyretic efficacy of oral paracetamol, intravenous paracetamol, and intramuscular diclofenac in patients presenting with fever to the emergency department.

Authors:  Firjeeth C Paramba; Vamanjore A Naushad; Nishan Purayil; Osama H Mohammed; Prem Chandra
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423

Review 6.  Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold.

Authors:  Denis M McCarthy
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-04       Impact factor: 3.043

7.  Adverse effects of non-steroidal anti-inflammatory drugs in patients with viral respiratory infections: rapid systematic review.

Authors:  Peter von Philipsborn; Renke Biallas; Jacob Burns; Simon Drees; Karin Geffert; Ani Movsisyan; Lisa Maria Pfadenhauer; Kerstin Sell; Brigitte Strahwald; Jan M Stratil; Eva Rehfuess
Journal:  BMJ Open       Date:  2020-11-19       Impact factor: 2.692

8.  Nonsteroidal anti-inflammatory drugs in acute viral respiratory tract infections: An updated systematic review.

Authors:  Nima Azh; Farzaneh Barzkar; Nogol Motamed-Gorji; Parmida Pourvali-Talatappeh; Yousef Moradi; Roya Vesal Azad; Mitra Ranjbar; Hamid Reza Baradaran
Journal:  Pharmacol Res Perspect       Date:  2022-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.